オスペミフェン
オスペミフェン 物理性質
- 沸点 :
- 544.6±50.0 °C(Predicted)
- 比重(密度) :
- 1.166±0.06 g/cm3(Predicted)
- 貯蔵温度 :
- Sealed in dry,2-8°C
- 溶解性:
- DMSO：可溶20mg/mL、透明
- 外見 :
- 粉
- 酸解離定数(Pka):
- 14.26±0.10(Predicted)
- 色:
- 白からベージュ
- InChIKey:
- LUMKNAVTFCDUIE-VHXPQNKSSA-N
- CAS データベース:
- 128607-22-7
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H410 |
長期的影響により水生生物に非常に強い毒性 |
水生環境有害性、慢性毒性 |
1 |
警告 |
|
P273, P391, P501 |
|
| 注意書き |
| P273 |
環境への放出を避けること。 |
| P501 |
内容物/容器を．．．に廃棄すること。 |
|
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
東京化成工業
|
O0441 |
オスペミフェン >98.0%(GC)
Ospemifene
>98.0%(GC) |
128607-22-7 |
100mg |
￥11900 |
2024-03-01 |
購入 |
|
東京化成工業
|
O0441 |
オスペミフェン >98.0%(GC)
Ospemifene
>98.0%(GC) |
128607-22-7 |
1g |
￥77500 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML0996 |
≥98% (HPLC)
Ospemifene ≥98% (HPLC) |
128607-22-7 |
10mg |
￥12700 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML0996 |
≥98% (HPLC)
Ospemifene ≥98% (HPLC) |
128607-22-7 |
50mg |
￥49100 |
2024-03-01 |
購入 |
オスペミフェン 化学特性,用途語,生産方法
外観
白色～ほとんど白色粉末～結晶
効能
骨粗鬆症治療薬, 選択的エストロゲン受容体モジュレータ (SERM)
説明
In February 2013, the US FDA approved ospemifene (also referred to as FC1271a), for the treatment ofmoderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), due tomenopause. It is estimated that there are 150 million postmenopausal women worldwide with 40–70% suffering from VVA. Ospemifene is a selective estrogen receptor (ER) modulator (SERM) and the first nonhormonal, nonestrogen for the treatment of moderate to severe dyspareunia in women with menopausal VVA. It binds to ERα (IC
50～800 nM) and ERβ (IC
50～1600 nM) with tissue-specific estrogenic agonist/antagonist effects. Treatment with ospemifene increases the thickness of the vaginal tissue thereby decreasing fragility of the tissue and reducing potential for pain during sexual intercourse.
使用
Treatment of vaginal atrophy, osteoporosis, and vasomotor symptoms.
定義
ChEBI: An organochlorine compound that is a selective estrogen receptor modulator; used for treatment of dyspareunia.
臨床応用
Ospemifene is a SERM that is currently in Phase II/III clinical trials for the treatment of postmenopausal
osteoporosis and urogenital atrophy. It is a known metabolite of toremifene, a triphenylethylene
derivative used to treat breast cancer.Ospemifene has been shown to have beneficial effects on the bone
without significant estrogen-related side effects. The beneficial effect observed on bone stems from this
agent's ability to increase osteoblast proliferation and, as a result, to enhance bone mineralization as well as
bone formation. Unlike tamoxifen, ospemifene does not induce osteocyte apoptosis.
オスペミフェン 上流と下流の製品情報
原材料
準備製品
オスペミフェン 生産企業
Global( 155)Suppliers
128607-22-7(オスペミフェン)キーワード:
- 128607-22-7
- 2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol
- 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-ethanol
- 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol
- Ccris 9205
- Fc-1271a
- Unii-B0p231ilbk
- Z-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol
- 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol
- 2-(4-(4-chloro-1
- 2-diphenyl-but-1-enyl)phenoxy)ethanol
- Ospemifene FC-1271a
- Ethanol,2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-
- CS-1039
- Ospemifene >
- 2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol USP/EP/BP
- Ospemifene D4Q: What is
Ospemifene D4 Q: What is the CAS Number of
Ospemifene D4 Q: What is the storage condition of
Ospemifene D4 Q: What are the applications of
Ospemifene D4
- Ospemifene
- The department of pp meters
- オスペミフェン
- 2-[4-[(Z)-4-クロロ-1,2-ジフェニル-2-ブテニル]フェノキシ]エタノール
- 2-{4-[(2Z)-4-クロロ-1,2-ジフェニルブタ-2-エン-1-イル]フェノキシ}エタン-1-オール
- FC-1271a